HC
BBIO icon

Henshaw Capital’s BridgeBio Pharma BBIO Stock Holding History

Henshaw Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,037
Closed -$677K – 173
2025
Q3 		$677K Buy
13,037
+4,781
+58% +$233K 0.03% 142
2025
Q2 		$356K Buy
+8,256
New +$300K 0.01% 266

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Henshaw Capital's BBIO Position: Q4 2025 in Review

Henshaw Capital sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 13,037 shares — an estimated $677K sold.

Henshaw Capital first reported a position in BBIO in Q2 2025 and held it in 2 quarters. The position peaked at $677K in Q3 2025. 435 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Henshaw Capital reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Henshaw Capital sold 13,037 BridgeBio Pharma shares in Q4 2025, an estimated $677K.
  • Henshaw Capital first reported a position in BridgeBio Pharma in Q2 2025 and held it in 2 quarters.
  • Henshaw Capital's BridgeBio Pharma position peaked at $677K in Q3 2025.
  • 435 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Henshaw Capital's 13F filing for Q4 2025, filed 28 May 2026.